How to view the current development of Chinese medicine

Panoramic view of the Chinese medicine industry chain

The composition of the Chinese medicine industry chain is relatively clear. The upstream includes mainly for the planting of Chinese herbal medicines as the main provider of Chinese herbal medicines, but also pre-mineral collection, animal breeding suppliers; the middle reaches for the production of Chinese medicine manufacturing link and processing link, including proprietary Chinese medicines, Chinese medicine tablets and Chinese medicine granules and other products; the downstream for the sale of Chinese medicines application platforms, including hospitals, pharmacies, supermarkets and e-commerce platforms, etc..

From the ecological mapping of the industry chain, the upstream Chinese herbal medicine planting representative enterprises include Xinbang Pharmaceutical, Dong'a Agaricus, Kunming Pharmaceutical Group, TIANSHI LIK, etc.; the midstream for the manufacturing and processing of Chinese medicine suppliers include Baiyunshan, Yunnan Baiyao, Buchang Pharmaceutical, Ealing Pharmaceutical, Pientzehuang, etc.; the downstream sales platform for traditional Chinese medicines are mainly hospitals, pharmacies, mainly listed pharmacy enterprises such as the common people's drugstore, Yifeng Pharmacy, etc., as well as emerging Chinese medicine e-commerce sales platforms such as Meituan and Taobao.

Distribution of enterprises in the traditional Chinese medicine industry chain

From the perspective of regional distribution of listed companies in the traditional Chinese medicine industry, Guangdong and Hunan regions have the largest number of listed enterprises in the traditional Chinese medicine industry. Among them, Baiyunshan, China Resources Sanjiu, Xiangxue Pharmaceutical Zhongsheng Pharmaceutical and other enterprises are located in Guangdong; Hunan region, there are Qianjin Pharmaceuticals, Qidian Pharmaceuticals, Jiuzhitang, the old people greatly pharmacy and other enterprises. In addition, the number of listed companies in Zhejiang, Yunnan, Shandong and other places are also more, Zhejiang Province, Shouxiangu, Kang Enbei and other enterprises, Yunnan Kunyao Group, Yunnan Baiyao, and so on.

Business Layout of Listed Enterprises of Traditional Chinese Medicine

From the perspective of business layout, Dong'a Ajiao, Tiansi, Yunnan Baiyao, Ealing Pharmaceuticals, Jichuan Pharmaceuticals, Pientzehuang and other enterprises of traditional Chinese medicine-related business revenue accounted for more than 60% of the company's total revenue; the regional layout, the traditional Chinese medicine companies are expanding their own sales network to the whole country, Tongrentang, Yunnan Baiyao, China Resources Sanjiu and other enterprises are also actively expanding overseas markets. In terms of specific business, most of the listed enterprises in China's traditional Chinese medicine industry have very competitive star products, such as Tianshili for ischemic heart disease market rankings in the compound danshen drip pills the first national market share, Dong'a Colla Corii Asini is a leader in Colla Corii Asini products, and so on.

Chinese medicine industry listed companies latest developments/business planning

Through the analysis of the latest developments or business planning of listed companies in the Chinese medicine industry, we can find that more and more Chinese medicine companies are no longer confined to the field of traditional Chinese medicine, and many of them are beginning to layout the pharmaceutical industry through new construction, joint ventures, cooperation and other ways. Many enterprises have begun to layout the pharmaceutical industry through new construction, joint ventures, cooperation and other ways, such as medical devices, health care and other fields. For example, Baiyunshan is actively laying out and investing in medical services, traditional Chinese medicine and health care, modern pension three major fields and medical equipment industry; step long pharmaceutical foreign investment reorganization of Changrui biological, enhance the enterprise biotechnology and CDMO R & D capabilities.

For more research and analysis of this industry, please refer to "China Traditional Chinese Medicine Industry Market Outlook and Investment Strategy Planning Analysis Report" by Prospect Industry Research Institute

.